Synopsis of recent research by authors named "Kyeonghui Kim"
- Kyeonghui Kim's recent research focuses on the role of genomic hypomethylation in predicting responses to immune checkpoint blockade (ICB) in cancer therapy, particularly in lung and breast cancer, utilizing a novel assay called iMethyl developed for analyzing cell-free DNA.
- Another key area of Kim's work investigates the immunogenicity of neoepitopes in human tumors, specifically in the context of MHC II and MHC I, leading to improved identification of functionally relevant neoepitopes through structural alignment analysis derived from a large dataset of immunogenicity assays.
- The findings indicate a promising avenue for enhancing personalized cancer treatment by linking epigenetic markers and immunogenic profiles to patient responses to checkpoint blockade therapies.
